Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | SVP & Chief Scientific Officer | January 29, 2021 | February 18, 2021 |
| BriaCell Therapeutics Corp.BCTX · Entity 7454 | Director | August 01, 2022 | August 01, 2022 |
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date January 29, 2021 · Filed February 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2031-01-29 | Direct | 16,500 |
Reported balance
After 2021-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-29 · Grant · Acquired 16,500 · Balance 16,500 F1: The option vests in three approximately equal annual installments beginning on January 29, 2022. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 5,500 |
Reported balance
After 2021-01-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-01-29 · Grant · Acquired 5,500 · Balance 5,500 F2: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3: The RSU vests in three approximately equal annual installments beginning on January 29, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in three approximately equal annual installments beginning on January 29, 2022.
F2: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis.
F3: The RSU vests in three approximately equal annual installments beginning on January 29, 2022.
BriaCell Therapeutics Corp.
Report date August 01, 2022 · Filed August 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.74 · Expires 2026-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed |
| Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.47 · Expires 2027-01-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2022-08-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The Option vests quarterly for 2 years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The Option vests quarterly for 2 years from the date of grant.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2017 Filed Feb 8, 2017 23:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 18,135 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-17-000109 · gross_4.xml · derivative · entry 3 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,608 Underlying: Common Stock · 18,135 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU converts into the Issuer's common stock on a one-for-one basis. F2 · derivative.exercise_date: On August 3, 2016, the reporting person was granted 36,271 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. F2 · derivative.expiration_date: On August 3, 2016, the reporting person was granted 36,271 RSUs, vesting in two equal installments on February 3, 2017 and February 3, 2018. Read SEC document |
| February 03, 2017 Filed Feb 8, 2017 23:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Tax withholdingCommon Stock | 5,922 | $1.92 | $11,370.24 |
DisclosureSEC source: 0001019056-17-000109 · gross_4.xml · nonDerivative · entry 2 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,871 Read SEC document |
| February 03, 2017 Filed Feb 8, 2017 23:26 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 18,135 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-17-000109 · gross_4.xml · nonDerivative · entry 1 Gross Jane A · CIK 0001684258 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU converts into the Issuer's common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.